These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 11157061

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Dendritic cells expand Epstein Barr virus specific CD8+ T cell responses more efficiently than EBV transformed B cells.
    Subklewe M, Sebelin K, Block A, Meier A, Roukens A, Paludan C, Fonteneau JF, Steinman RM, Münz C.
    Hum Immunol; 2005 Sep; 66(9):938-49. PubMed ID: 16360833
    [Abstract] [Full Text] [Related]

  • 3. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.
    Münz C, Bickham KL, Subklewe M, Tsang ML, Chahroudi A, Kurilla MG, Zhang D, O'Donnell M, Steinman RM.
    J Exp Med; 2000 May 15; 191(10):1649-60. PubMed ID: 10811859
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.
    Kalra M, Gerdemann U, Luu JD, Ngo MC, Leen AM, Louis CU, Rooney CM, Gottschalk S.
    Cytotherapy; 2019 Feb 15; 21(2):212-223. PubMed ID: 30396848
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Reinforcement of cell-mediated immunity driven by tumor-associated Epstein-Barr virus (EBV)-specific T cells during targeted B-cell therapy with rituximab.
    Tischer-Zimmermann S, Bonifacius A, Santamorena MM, Mausberg P, Stoll S, Döring M, Kalinke U, Blasczyk R, Maecker-Kolhoff B, Eiz-Vesper B.
    Front Immunol; 2023 Feb 15; 14():878953. PubMed ID: 37033971
    [Abstract] [Full Text] [Related]

  • 9. Induction of autologous CD4- and CD8-mediated T-cell responses against acute lymphocytic leukemia cell line using apoptotic tumor cell-loaded dendritic cells.
    Hatakeyama N, Tamura Y, Sahara H, Suzuki N, Suzuki K, Hori T, Mizue N, Torigoe T, Tsutsumi H, Sato N.
    Exp Hematol; 2006 Feb 15; 34(2):197-207. PubMed ID: 16459188
    [Abstract] [Full Text] [Related]

  • 10. Cyclical expression of EBV latent membrane protein 1 in EBV-transformed B cells underpins heterogeneity of epitope presentation and CD8+ T cell recognition.
    Brooks JM, Lee SP, Leese AM, Thomas WA, Rowe M, Rickinson AB.
    J Immunol; 2009 Feb 15; 182(4):1919-28. PubMed ID: 19201845
    [Abstract] [Full Text] [Related]

  • 11. Robust T-cell stimulation by Epstein-Barr virus-transformed B cells after antigen targeting to DEC-205.
    Leung CS, Maurer MA, Meixlsperger S, Lippmann A, Cheong C, Zuo J, Haigh TA, Taylor GS, Münz C.
    Blood; 2013 Feb 28; 121(9):1584-94. PubMed ID: 23297134
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Presentation of epstein-barr virus latency antigens to CD8(+), interferon-gamma-secreting, T lymphocytes.
    Subklewe M, Chahroudi A, Bickham K, Larsson M, Kurilla MG, Bhardwaj N, Steinman RM.
    Eur J Immunol; 1999 Dec 28; 29(12):3995-4001. PubMed ID: 10602009
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination.
    Ranieri E, Herr W, Gambotto A, Olson W, Rowe D, Robbins PD, Kierstead LS, Watkins SC, Gesualdo L, Storkus WJ.
    J Virol; 1999 Dec 28; 73(12):10416-25. PubMed ID: 10559360
    [Abstract] [Full Text] [Related]

  • 17. The impact of HLA class I and EBV latency-II antigen-specific CD8(+) T cells on the pathogenesis of EBV(+) Hodgkin lymphoma.
    Jones K, Wockner L, Brennan RM, Keane C, Chattopadhyay PK, Roederer M, Price DA, Cole DK, Hassan B, Beck K, Gottlieb D, Ritchie DS, Seymour JF, Vari F, Crooks P, Burrows SR, Gandhi MK.
    Clin Exp Immunol; 2016 Feb 28; 183(2):206-20. PubMed ID: 26422112
    [Abstract] [Full Text] [Related]

  • 18. Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma.
    Fogg MH, Wirth LJ, Posner M, Wang F.
    Proc Natl Acad Sci U S A; 2009 Mar 03; 106(9):3318-23. PubMed ID: 19211798
    [Abstract] [Full Text] [Related]

  • 19. Dendritic cells for the induction of EBV immunity.
    Subklewe M.
    Recent Results Cancer Res; 2002 Mar 03; 159():38-43. PubMed ID: 11785842
    [Abstract] [Full Text] [Related]

  • 20. CD8 T cell recognition of endogenously expressed epstein-barr virus nuclear antigen 1.
    Lee SP, Brooks JM, Al-Jarrah H, Thomas WA, Haigh TA, Taylor GS, Humme S, Schepers A, Hammerschmidt W, Yates JL, Rickinson AB, Blake NW.
    J Exp Med; 2004 May 17; 199(10):1409-20. PubMed ID: 15148339
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.